Director

Daniel J. Starks

Director·Abbott Laboratories

About

Daniel J. Starks served as Chairman, President and Chief Executive Officer of St. Jude Medical, Inc., a medical device manufacturer, from 2004 until his retirement in January 2016, and as Executive Chairman of the Board from January 2016 to January 2017, when Abbott completed its acquisition of St. Jude Medical.

He joined St. Jude Medical in 1996 and joined Abbott's Board of Directors in 2017.

Since 2017
Age 71
Tenure 9 yrs

Also at Abbott Laboratories

NM Nita Ahuja, M.D. Director RM Robert J. Alpern, M.D. Director CB Claire Babineaux-Fontenot Director SP Sally E. Blount, Ph.D. Director RF Robert B. Ford Chairman of the Board and Chief Executive Officer; Director PG Paola Gonzalez Director

Roles

Organization Role Dates Details
Abbott Laboratories Director 2017–present Current role
St. Jude Medical, Inc. Executive Chairman of the Board January 2016 to January 2017 A medical device manufacturer; ended when Abbott completed its acquisition of St. Jude Medical.
St. Jude Medical, Inc. Chairman, President and Chief Executive Officer 2004 to January 2016
St. Jude Medical, Inc. President and Chief Operating Officer 2001 to 2004
St. Jude Medical, Inc. President and CEO, Cardiac Rhythm Management Business 1997 to 2001

Related

Company Abbott Laboratories Company hub Person Nita Ahuja, M.D. Director Person Robert J. Alpern, M.D. Director Person Claire Babineaux-Fontenot Director Person Sally E. Blount, Ph.D. Director Person Robert B. Ford Chairman of the Board and Chief Executive Officer; Director Person Paola Gonzalez Director Person Michelle A. Kumbier Director Person Darren W. McDew Director Person Nancy McKinstry Lead Independent Director Person Michael G. O'Grady Director Person Michael F. Roman Director Person John G. Stratton Director Deal Abbott Laboratories Advanced Medical Optics 2009 Deal page Deal Abbott Laboratories Alere 2017 Deal page Deal Abbott Laboratories Basf S Pharmaceutical Business Knoll 2001 Deal page
Source: Abbott Laboratories proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo